

---

## Litium - More Brains, More Geins

Redeye provides an update following Litium's acquisition of Geins, a small but strategically sound deal that brings both technical capabilities and a customer base of some 25 clients. The transaction adds ~11% to ARR and the 6% rights issue discount and broad insider participation reflect strong backing. We lift our estimates slightly across the board.

**Read more and download the Research Update.**

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. [www.redeye.se/](http://www.redeye.se/)

### Attachments

---

**Litium - More Brains, More Geins**